{
  "id": "641d8fd6690f196b51000041",
  "type": "list",
  "question": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?",
  "ideal_answer": "The serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity include neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and GFAP/NfL.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33724534",
    "http://www.ncbi.nlm.nih.gov/pubmed/31425702",
    "http://www.ncbi.nlm.nih.gov/pubmed/35635574",
    "http://www.ncbi.nlm.nih.gov/pubmed/34278578",
    "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
    "http://www.ncbi.nlm.nih.gov/pubmed/35898513",
    "http://www.ncbi.nlm.nih.gov/pubmed/35938660",
    "http://www.ncbi.nlm.nih.gov/pubmed/34212756"
  ],
  "snippets": [
    {
      "text": "multiple sclerosis, AQP4-IgG-positive neuromyelitis optica spectrum disorder, and MOG-IgG-associated disorde",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31425702",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG) discovered in 2004 was found to be both the pathologic cause and a reliable biomarker for neuromyelitis optica spectrum disorders",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31425702",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34212756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "GFAP might be the most appropriate for monitoring NMOSD longitudinally, which warrants future confirming studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34212756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We prospectively recruited consecutive NMOSD patients with anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12\u2009months of follow-up (main period), and at attacks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34212756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "During the study, five (8%) patients developed new attacks; only serum GFAP levels increased consistently upon these events compared with baseline levels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34212756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Neuromyelitis optica (NMO) is an inflammatory disease that resembles MS in the relapsing clinical course of optic neuritis and myelitis. Two decades of studies have revealed that autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4)\u00a0are detected in the core group of patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35635574",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "During the acute phase of NMOSD and MOGAD, plasma C3 and C4 may become potential biomarkers for distinguishing the two diseases and reflecting the NMOSD BBB damage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35898513",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody and characterization of NMOSD as an autoimmune astrocytopathy have spearheaded the identification of key immunologic therapeutic targets in this disease, including but not limited to the complement system, the interleukin 6 (IL-6) receptor, and B cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938660",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". As our understanding regarding the immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP), may facilitate earlier relapse detection and inform long-term treatment decisions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938660",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We investigated the serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels in a cohort of Chinese patients with neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) in relation to clinical disease course and treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34278578",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33724534",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: To test the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments, respectively, are clinically useful biomarkers of disease activity and disability in neuromyelitis optica spectrum disorders (NMOSD).METHODS: Levels of GFAP and NfL in serum (sGFAP and sNfL, respectively) and in CSF samples were measured in healthy controls (HCs) (n = 49; 49 serum samples), patients with NMOSD (n = 33; 42 CSF and 102 serum samples), and patients with multiple sclerosis (MS) (n = 49; 53 CSF and 91 serum samples) by ultrasensitive single-mo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "GFAP, glial fibrillary acidic protein, anti-aquaporin-4 antibody, quaporin-4 (AQP4)-immunoglobulin G (IgG), Plasma C3, Plasma C4, serum neurofilament light chain"
}